# Empagliflozin in ESKD - A Feasibility Study

> **NCT05687058** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Mississippi Medical Center** · enrollment: 24 (estimated)

## Conditions studied

- Kidney Failure, Chronic
- Heart Failure

## Interventions

- **DRUG:** Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing
- **DRUG:** Empagliflozin 10 mg daily dosing

## Key facts

- **NCT ID:** NCT05687058
- **Lead sponsor:** University of Mississippi Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2025-10-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05687058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05687058, "Empagliflozin in ESKD - A Feasibility Study". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05687058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*